Article in American journal of physiology. Heart and circulatory physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Boyu XiaDepartment of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States.
Huilong ChenDepartment of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States.
Sarah J TalebDepartment of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States.ORCID 0009-0001-2541-8580
Xiaoqing XiDepartment of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States.
Nargis ShaheenDepartment of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States.
Boina BaoyinnaDepartment of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States.ORCID 0000-0003-3700-7292
Sourabh SoniDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, United States.ORCID 0000-0002-2323-1245
Yohannes A MebratuDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, United States.ORCID 0000-0002-5360-2158
Jacob S YountDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, Ohio, United States.
Jing ZhaoDepartment of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States.
Yutong ZhaoDepartment of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States.ORCID 0000-0001-6604-9315
Funding
Mechanisms of innate resistance to virus infectionsR01AI130110 · NIAID · OHIO STATE UNIVERSITY · PI Jacob Yount · 2017 to 2026
$4.3M
Protein therapy to treat virus induced cardiopulmonary injuryR01HL157215 · NHLBI · UNIVERSITY OF VIRGINIA · PI CAI, CHUANXI, MA, JIANJIE · 2022 to 2025
$2.7M
Molecular regulation of immunoproteasome assembly in inflammatory diseasesR01HL167846 · NHLBI · OHIO STATE UNIVERSITY · PI JING ZHAO · 2023 to 2026
$2.4M
Mechanistic characterization of a new master regulator of cardiac virus infectionsR01HL154001 · NHLBI · OHIO STATE UNIVERSITY · PI ACCORNERO, FEDERICA, YOUNT, JACOB · 2020 to 2023
$2.3M
ISGylation regulates lung endothelial inflammationR01HL157164 · NHLBI · OHIO STATE UNIVERSITY · PI ZHAO, YUTONG · 2021 to 2024
$2.2M
The role of Bik in the replication and severity of influenza A virusR01AI148180 · NIAID · OHIO STATE UNIVERSITY · PI MEBRATU, YOHANNES AFEWORK · 2021 to 2025
$2.1M
Molecular regulation of BMPRII stability in lung fibrosisR01HL169203 · NHLBI · OHIO STATE UNIVERSITY · PI Yutong Zhao · 2023 to 2026
$2.0M
Deubiquitinating and inhibiting Hsp90 by USP40 mitigates lung injuryR01HL151513 · NHLBI · OHIO STATE UNIVERSITY · PI ZHAO, JING · 2020 to 2023
$1.7M
Foundation for the National Institutes of Health (FNIH) R01AI148180Foundation for the National Institutes of Health (FNIH) R01HL136284; R01HL157164Foundation for the National Institutes of Health (FNIH) R01HL151513; R01HL167846| International Institute for Carbon-Neutral Energy Research, Kyushu Universitytitutes of Health R01AI130110NHLBI NIH HHS R01 HL151513NHLBI NIH HHS R01 HL157164NHLBI NIH HHS R01 HL167846NHLBI NIH HHS R01 HL169203NIAID NIH HHS R01 AI130110NIAID NIH HHS R01 AI148180
6 · The paper itself
Abstract
Influenza A virus (IAV) infection while primarily affecting the lungs, is often associated with cardiovascular complications. However, the mechanisms underlying this association are not fully understood. Here, we investigated the potential role of FBXL19, a member of the Skp1-Cullin-1-F-box family of E3 ubiquitin ligase, in IAV-induced cardiac inflammation. We demonstrated that FBXL19 overexpression in endothelial cells (ECs) reduced viral titers and IAV matrix protein 1 (M1) levels while increasing antiviral gene expression, including interferon (IFN)-α, -β, and -γ and RANTES (regulated on activation normal T cell expressed and secreted) in the cardiac tissue of IAV-infected mice. Moreover, EC-specific overexpression of FBXL19 attenuated the IAV infection-reduced interferon regulatory factor 3 (IRF3) level without altering its mRNA level and suppressed cardiac inflammation. Furthermore, IAV infection triggered cellular senescence programs in the heart as indicated by the upregulation of p16 and p21 mRNA levels and the downregulation of lamin-B1 levels, which were partially reversed by FBXL19 overexpression in ECs. Our findings indicate that EC-specific overexpression of FBXL19 protects against IAV-induced cardiac damage by enhancing interferon-mediated antiviral signaling, reducing cardiac inflammation, and suppressing cellular senescence programs.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
FBXL19 in endothelial cells protects the heart from influenza A infection by enhancing antiviral immunity and reducing cellular senescence programs. · full record | OpenQuestion